Effect of p-chlorophenylalanine on the acquisition of tolerance to barbital. 1980

A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc

The effect of p-chlorophenylalanine (p-CPA) pretreatment on barbital tolerance in the rat as measured by motor impairment on the moving belt test was examined in two separate studies. The first used a 2 X 2 design with doses of p-CPA (125 mg/kg) or water, and sodium barbital (300 mg/kg) or water. The treatments continued for 28 days with tests every 7 days. The p-CPA dose used was previously shown to produce and maintain greater than 95% depletion of brain serotonin (5-HT). Tolerance developed to the test doses, and even greater tolerance to the chronic treatment doses. In both cases the p-CPA slowed the development of tolerance without altering the acute response to the challenge dose of barbital. The second study involved only a p-CPA-barbital group and a water-barbital group. In this case treatment lasted for up to 8 days, with separate subgroups being tested only once each at 2-day intervals, in order to prevent the tests from affecting the rate of tolerance development. This experiment confirmed that p-CPA slowed the development of barbital tolerance. The present findings provide additional support for the possibility that 5-HT may be involved in the development of tolerance to sedatives (e.g., alcohol, pentobarbital).

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D010134 Fenclonine A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin. p-Chlorophenylalanine,para-Chlorophenylalanine,CP-10,188,DL-3-(4-Chlorophenyl)alanine,Fenclonin,Fenclonine (L)-Isomer,Fenclonine Hydrobromide,Fenclonine Hydrochloride,Fenclonine, (D)-Isomer,Hydrobromide, Fenclonine,Hydrochloride, Fenclonine,para Chlorophenylalanine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001462 Barbital A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbitone,Diethylmalonylurea,Ethylbarbital,Diemal,Dormileno,Medinal,Veronal
D001463 Barbiturates A class of chemicals derived from barbituric acid or thiobarbituric acid. Many of these are GABA MODULATORS used as HYPNOTICS AND SEDATIVES, as ANESTHETICS, or as ANTICONVULSANTS.

Related Publications

A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
November 1975, Psychopharmacologia,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
May 1978, Psychopharmacology,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
August 1977, Canadian journal of physiology and pharmacology,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
February 1971, Science (New York, N.Y.),
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
April 1971, The Journal of pharmacology and experimental therapeutics,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
April 1979, Pharmacology, biochemistry, and behavior,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
September 1967, The Journal of pharmacy and pharmacology,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
February 1983, The American journal of physiology,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
May 1969, British journal of pharmacology,
A D Lê, and J M Khanna, and H Kalant, and A E LeBlanc
July 1972, Electroencephalography and clinical neurophysiology,
Copied contents to your clipboard!